Načítá se...
RAS and BRAF in metastatic colorectal cancer management
The treatment of metastatic colorectal cancer (mCRC) has been further refined with the development of monoclonal antibodies, cetuximab and panitumumab, towards the epidermal growth factor receptor (EGFR). Anti-EGFR therapy has afforded improved survival in those with wild-type RAS mCRC but provides...
Uloženo v:
| Vydáno v: | J Gastrointest Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5056249/ https://ncbi.nlm.nih.gov/pubmed/27747083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.06.12 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|